Phase 3 Randomized Study of Teclistamab and Talquetamab (Tec-Tal) Versus Daratumumab and Lenalidomide (DR) in Minimal Residual Disease (MRD) Positive Patients With Newly Diagnosed Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation (TiTan)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-525097-11-00

Enrollment

248

Registered

2026-07-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Brief summary

MRD-CR negativity (10^-5) with complete response at Month 12

Detailed description

Progression-free survival (PFS), Complete response (CR) or better, PFS2 (progression‑free survival to second disease progression or death), Overall survival (OS), Incidence and severity of AEs, Incidences of SAEs, MRD negativity (10^-5), Sustained MRD negativity (10^-5) for at least 12 months, • Time to worsening of symptoms • Mean change from baseline in the EORTC QLQ-C30 global health status and functional scale scores (including MY-20)

Interventions

DRUGJNJ-64407564

DRUGDARZALEX 1800 mg solution for injection

DRUGRevlimid 15 mg hard capsules

DRUGteclistamab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
MRD-CR negativity (10^-5) with complete response at Month 12	—

Secondary

Measure	Time frame
Progression-free survival (PFS), Complete response (CR) or better, PFS2 (progression‑free survival to second disease progression or death), Overall survival (OS), Incidence and severity of AEs, Incidences of SAEs, MRD negativity (10^-5), Sustained MRD negativity (10^-5) for at least 12 months, • Time to worsening of symptoms • Mean change from baseline in the EORTC QLQ-C30 global health status and functional scale scores (including MY-20)	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 24, 2026